Immunocore Holdings PLC reports results for the quarter ended June 30 - Earnings Summary
07/08/2025 18:17
Immunocore Holdings PLC IMCR.OQ reported a quarterly adjusted loss of 20 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -23 cents. The mean expectation of fifteen analysts for the quarter was for a loss of 21 cents per share. Wall Street expected results to range from -51 cents to -5 cents per share. Revenue rose 30% to $97.96 million from a year ago; analysts expected $94.77 million. Immunocore Holdings PLC's reported EPS for the quarter was a loss of 20 cents. The company reported a quarterly loss of $10.3 million. Immunocore Holdings PLC shares had risen by 2.3% this quarter and gained 8.8% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 18.8% in the last three months. In the last 30 days, there have been no negative revisions of earnings estimates RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" Wall Street's median 12-month price target for Immunocore Holdings PLC is $66.00, about 51.4% above its last closing price of $32.10 This summary was machine generated from LSEG data August 7 at 05:16 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -0.21 | -0.20 | Beat |
| Mar. 31 2025 | -0.39 | 0.10 | Beat |
| Dec. 31 2024 | -0.26 | -0.47 | Missed |
| Sep. 30 2024 | -0.35 | 0.17 | Beat |